168 related articles for article (PubMed ID: 38381257)
21. Diagnostic challenges, management and outcomes of midline low-grade gliomas.
Waqar M; Hanif S; Rathi N; Das K; Zakaria R; Brodbelt AR; Walker C; Jenkinson MD
J Neurooncol; 2014 Nov; 120(2):389-98. PubMed ID: 25096797
[TBL] [Abstract][Full Text] [Related]
22. Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy.
Wang PG; Li YT; Pan Y; Gao ZZ; Guan XW; Jia L; Liu FT
J Neurooncol; 2019 Jan; 141(1):71-81. PubMed ID: 30446901
[TBL] [Abstract][Full Text] [Related]
23. Administration of Valproic Acid Improves the Survival of Patients with Glioma Treated with Postoperative Radiotherapy.
Wang G; Guan S; Yang X; Sun S; Huang B; Li X
Oncol Res Treat; 2022; 45(11):650-659. PubMed ID: 35988539
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas.
Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q
World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756
[TBL] [Abstract][Full Text] [Related]
25. The role of adjuvant chemotherapy in patients with H3K27 altered diffuse midline gliomas: a multicentric retrospective study.
Di Nunno V; Lombardi G; Simonelli M; Minniti G; Mastronuzzi A; Di Ruscio V; Corrà M; Padovan M; Maccari M; Caccese M; Simonetti G; Berlendis A; Farinotti M; Pollo B; Antonelli M; Di Muzio A; Dipasquale A; Asioli S; De Biase D; Tosoni A; Silvani A; Franceschi E
J Neurooncol; 2024 Mar; 167(1):145-154. PubMed ID: 38457090
[TBL] [Abstract][Full Text] [Related]
26. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.
Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A
JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Li F; Zhang Y; Wang N; Song C; Gao Y; Diao X; Zhang H
World Neurosurg; 2020 Jun; 138():663-671. PubMed ID: 31981784
[TBL] [Abstract][Full Text] [Related]
28. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Sirachainan N; Pakakasama S; Visudithbhan A; Chiamchanya S; Tuntiyatorn L; Dhanachai M; Laothamatas J; Hongeng S
Neuro Oncol; 2008 Aug; 10(4):577-82. PubMed ID: 18559468
[TBL] [Abstract][Full Text] [Related]
29. A nomogram combining inflammatory markers and clinical factors predicts survival in patients with diffuse glioma.
Yan P; Li JW; Mo LG; Huang QR
Medicine (Baltimore); 2021 Nov; 100(47):e27972. PubMed ID: 34964788
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
31. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
32. [Survival of newly diagnosed malignant glioma patients on combined modality therapy].
Yang QY; Shen D; Sai K; Jiang XB; Ke C; Zhang XH; Mou YG; Chen ZP
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(1):8-10. PubMed ID: 23578444
[TBL] [Abstract][Full Text] [Related]
33. Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment.
Forster MT; Hug M; Geissler M; Voss M; Weber K; Hoelter MC; Seifert V; Czabanka M; Steinbach JP
J Cancer Res Clin Oncol; 2023 Jan; 149(1):111-119. PubMed ID: 36348019
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Factors for Survival Outcome of High-Grade Multicentric Glioma.
Wang T; Niu X; Gao T; Zhao L; Li J; Gan Y; Liu Y; Mao Q
World Neurosurg; 2018 Apr; 112():e269-e277. PubMed ID: 29337167
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing survival in high-grade gliomas.
Buckner JC
Semin Oncol; 2003 Dec; 30(6 Suppl 19):10-4. PubMed ID: 14765378
[TBL] [Abstract][Full Text] [Related]
36. Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma.
Jo J; Williams B; Smolkin M; Wintermark M; Shaffrey ME; Lopes MB; Schiff D
J Neurooncol; 2014 Oct; 120(1):155-61. PubMed ID: 25038848
[TBL] [Abstract][Full Text] [Related]
37. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
[TBL] [Abstract][Full Text] [Related]
38. High-grade Glioma - A decade of care in Christchurch.
Yan SS; James ML; Kerstens P; de Lambert M; Robinson BA; Yi M
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):665-673. PubMed ID: 31464076
[TBL] [Abstract][Full Text] [Related]
39. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.
Gnekow AK; Falkenstein F; von Hornstein S; Zwiener I; Berkefeld S; Bison B; Warmuth-Metz M; Driever PH; Soerensen N; Kortmann RD; Pietsch T; Faldum A
Neuro Oncol; 2012 Oct; 14(10):1265-84. PubMed ID: 22942186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
